HC Wainwright Weighs in on SpringWorks Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:SWTX)

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) – Stock analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for SpringWorks Therapeutics in a report issued on Thursday, August 8th. HC Wainwright analyst R. Burns expects that the company will earn $0.11 per share for the year. HC Wainwright currently has a “Buy” rating and a $74.00 target price on the stock. The consensus estimate for SpringWorks Therapeutics’ current full-year earnings is ($4.62) per share.

SpringWorks Therapeutics (NASDAQ:SWTX) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.58. The firm had revenue of $59.73 million during the quarter, compared to analyst estimates of $34.42 million. During the same period last year, the business earned ($1.25) EPS. The firm’s revenue was up 59732900.0% compared to the same quarter last year.

Separately, Wedbush reissued an “outperform” rating and issued a $75.00 price objective on shares of SpringWorks Therapeutics in a research report on Wednesday. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $68.83.

SpringWorks Therapeutics Price Performance

SWTX traded up $0.39 during trading hours on Friday, reaching $36.31. 10,975 shares of the stock traded hands, compared to its average volume of 985,443. SpringWorks Therapeutics has a fifty-two week low of $18.00 and a fifty-two week high of $53.92. The company has a market cap of $2.69 billion, a price-to-earnings ratio of -6.99 and a beta of 0.78. The firm’s fifty day simple moving average is $37.69 and its two-hundred day simple moving average is $43.18.

Institutional Investors Weigh In On SpringWorks Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of SWTX. Russell Investments Group Ltd. grew its position in shares of SpringWorks Therapeutics by 49.0% in the 1st quarter. Russell Investments Group Ltd. now owns 170,047 shares of the company’s stock worth $8,370,000 after acquiring an additional 55,893 shares in the last quarter. Seven Eight Capital LP acquired a new position in SpringWorks Therapeutics in the fourth quarter worth $1,544,000. Price T Rowe Associates Inc. MD increased its stake in SpringWorks Therapeutics by 48.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,110,462 shares of the company’s stock valued at $202,318,000 after purchasing an additional 1,333,892 shares during the last quarter. Perceptive Advisors LLC raised its holdings in shares of SpringWorks Therapeutics by 28.7% during the fourth quarter. Perceptive Advisors LLC now owns 1,957,246 shares of the company’s stock worth $71,439,000 after purchasing an additional 436,830 shares during the period. Finally, Point72 Asset Management L.P. boosted its holdings in shares of SpringWorks Therapeutics by 310.7% in the 4th quarter. Point72 Asset Management L.P. now owns 2,162,176 shares of the company’s stock valued at $78,919,000 after buying an additional 1,635,722 shares during the period.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.